Alexandria, VA – January 17, 2024 – The Innovation and Value Initiative (IVI), a non-profit research organization committed to advancing the science, practice, and use of value assessment in health care, today announced the addition of four new members to its 2024 Board of Directors: Scott Brunner, Susan A. Cantrell, RPh, MHL, CAE, Lisa Bo Feng, DrPH, and Kistein Monkhouse, MPA. They will start their three-year term of service in January 2024.

“We welcome new IVI board members with diverse backgrounds, extensive experience, and unwavering commitment to our mission,” said IVI’s Chief Executive Officer, Jason Spangler, MD, MPH, FACPM. “Their insights and expertise will help guide us in advancing patient-centered health technology assessment for better outcomes and more equitable healthcare.”

I’m excited to contribute to IVI’s work to advance best practices in value assessment. I hope my participation on the Board of Directors will help bring state level perspectives to IVI’s work including bringing patient voices to the research effort and promoting health equity in rural areas and among patients with disabilities.

Scott Brunner, Kansas Department of Aging and Disability Services

Scott Brunner is the Deputy Secretary of Hospitals and Facilities with the Kansas Department of Aging and Disability Services (KDADS). This position provides executive oversight of the four state hospitals and the KDADS staff conducting surveys and certification reviews for long-term care facilities and health occupations.

I am honored to join the board of IVI as we work collectively to advance patient-centered health technology assessment, provide valuable insights to support healthcare decision-making, and improve equity in our nation’s healthcare system.

Susan A. Cantrell, RPh, MHL, CAE, Academy of Managed Care Pharmacy

Susan Cantrell is Chief Executive Officer of the Academy of Managed Care Pharmacy (AMCP), the national professional society whose members manage medication therapy benefits for the over 300 million Americans covered by public and private health plans. Susan leads the organization in fulfilling its mission of increasing patient access to affordable medicines, improving health outcomes, and ensuring the wise use of healthcare dollars.

Joining IVI’s board is an incredible opportunity to serve patients, especially those living with rare diseases. I’m excited to contribute to IVI’s mission to promote equitable care and access by advancing the way we collect data and generate evidence to better reflect the diversity of patient population. No other organization convenes, solicits, and embeds stakeholder perspectives like IVI – it’s in their DNA.

Lisa Bo Feng, DrPH, Alexion, AstraZeneca Rare Disease

Lisa Feng, DrPH is the Senior Director of Health policy at Alexion, AstraZeneca Rare Disease, which focuses on transforming the lives of people affected by rare diseases and devastating conditions. In her role at Alexion, Dr. Feng helps the company assess the evolving health policy landscape to lead efforts that help ensure patient access to current and future innovations.

I am thrilled to have been chosen to join the board of IVI, and I am committed to contributing to the advancement of its mission in a meaningful and equitable manner throughout my tenure.

Kistein Monkhouse, MPA, Patient Orator

Kistein Monkhouse, MPA, is a patient advocate for health equity and women’s rights. She is the Chief Executive Officer and founder of Patient Orator, a digital health solution organization, powering meaningful communication between individuals and their health teams to improve health outcomes.

The new appointments to the Board will join the following 2024 Board members: Mark Cziraky, PharmD – President (President, Carelon Research), Greg Daniel, PhD (Head of U.S. Healthcare Policy, Eli Lilly), Patty Fritz, MA – Treasurer and Secretary (Vice President, U.S. Corporate Affairs, UCB ), Alan Balch, PhD (Chief Executive Officer, Patient Advocate Foundation and National Patient Advocate Foundation), Harold Carter, PharmD (Vice President, Strategy & Contracting, Express Scripts), Chuck Cutler, MD, MS (President, Cutler Healthcare), Nelly Ganesan, MPH (Executive Director of Community Engagement and Health Equity, JPMorgan Chase & Co. – Morgan Health), Suzanne Schrandt (Founder and Chief Executive Officer of ExPPect), Vipan C. Sood, MBA, RPh, MRPharmS – President-Elect (President, vcsood Consulting), Adam Thompson (consultant) Ashley Valentine, MRes (Co-Founder & President, Sick Cells), and Neil Weissman, MD (President, MedStar Health Research Institute).


About IVI
The Innovation and Value Initiative (IVI) is a 501(c)(3) tax-exempt, non-profit research organization dedicated to advancing the science and improving the practice of value assessment through development of novel methods and the creation and application of enhanced value assessment models to support local decision-making needs in healthcare.

Contact: Tiffany Huth, MPH
Phone: 202.487.8057